The global thalassemia market size is expected to be valued at USD 1.43 billion by 2030, exhibiting a CAGR of 7.8% from 2024 to 2030. Increase in demand for a universal cure, rise in awareness about the disease, and technological advancements are likely to increase the adoption of gene therapies.
Thalassemia is a general term for a group of inheritable blood disorders, in which the body produces abnormal hemoglobin, resulting in the destruction of red blood cells. This ultimately leads to anemia. There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia, the latter being more serious. Beta-thalassemia is a common autosomal recessive disorder worldwide and it is relatively rare in the U.S.
Increase in the incidence of thalassemia is anticipated to fuel market growth. Despite technological advancements, the unmet need for a reliable treatment option still exists. Treatment of thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy. Drugs prescribed for thalassemia mostly cure symptoms and side effects such as anemia, iron overload, and vitamin deficiency. However, gene therapy is emerging as a reliable treatment option for the disease.
Prevalence of thalassemia is reported to increase gradually over the years across different regions. This can be attributed to population migration, intermarriages, and genetic and environmental factors prompting the condition and its implications.
This product will be delivered within 1-3 business days.
Thalassemia is a general term for a group of inheritable blood disorders, in which the body produces abnormal hemoglobin, resulting in the destruction of red blood cells. This ultimately leads to anemia. There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia, the latter being more serious. Beta-thalassemia is a common autosomal recessive disorder worldwide and it is relatively rare in the U.S.
Increase in the incidence of thalassemia is anticipated to fuel market growth. Despite technological advancements, the unmet need for a reliable treatment option still exists. Treatment of thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy. Drugs prescribed for thalassemia mostly cure symptoms and side effects such as anemia, iron overload, and vitamin deficiency. However, gene therapy is emerging as a reliable treatment option for the disease.
Prevalence of thalassemia is reported to increase gradually over the years across different regions. This can be attributed to population migration, intermarriages, and genetic and environmental factors prompting the condition and its implications.
Thalassemia Market Report Highlights
- The iron chelating drugs segment held the largest revenue share of 52.7% in 2023. Patients with thalassemia often require regular blood transfusions, which can lead to iron overload in the body.
- The beta thalassemia held the largest revenue share of 71.2% in 2023. Ongoing advancements in diagnostic techniques and treatment options for beta thalassemia have significantly improved patient outcomes.
- North America thalassemia market dominated the global market with a revenue share of 42.8% in 2023.
The leading players in the Thalassemia market include:
- CHIESI Farmaceutici S.p.A.
- Bristol-Myers Squibb Company
- Sun Pharmaceutical Industries Ltd.
- Cipla
- Fresenius Kabi AG
- Novartis Pharmaceuticals Corporation
- Apotex Inc.
- bluebird bio, Inc.
- Vertex Pharmaceuticals Incorporated
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Thalassemia Market Variables, Trends, & Scope
Chapter 4. Thalassemia Market: Treatment Estimates & Trend Analysis
Chapter 5. Thalassemia Market: Type Estimates & Trend Analysis
Chapter 6. Thalassemia Market: Regional Estimates & Trend Analysis
Chapter 7. Competitive Landscape
Companies Mentioned
The leading players in the Thalassemia market include:- CHIESI Farmaceutici S.p.A.
- Bristol-Myers Squibb Company
- Sun Pharmaceutical Industries Ltd.
- Cipla
- Fresenius Kabi AG
- Novartis Pharmaceuticals Corporation
- Apotex Inc.
- bluebird bio, Inc.
- Vertex Pharmaceuticals Incorporated
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 850 Million |
| Forecasted Market Value ( USD | $ 1430 Million |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
